vs
Side-by-side financial comparison of Bionano Genomics, Inc. (BNGO) and EyePoint, Inc. (EYPT). Click either name above to swap in a different company.
Bionano Genomics, Inc. is the larger business by last-quarter revenue ($8.0M vs $619.0K, roughly 12.8× EyePoint, Inc.). Bionano Genomics, Inc. runs the higher net margin — -99.8% vs -10922.3%, a 10822.5% gap on every dollar of revenue. On growth, Bionano Genomics, Inc. posted the faster year-over-year revenue change (-2.6% vs -94.7%). Over the past eight quarters, Bionano Genomics, Inc.'s revenue compounded faster (-4.8% CAGR vs -77.0%).
Bionano Genomics develops and commercializes proprietary optical genome mapping technology and diagnostic solutions. Its products detect large structural genomic variants with high precision, serving global research institutions, biopharma firms, and clinical labs for oncology, rare disease, and reproductive health use cases.
EyePoint Pharmaceuticals Inc. is a Watertown, Massachusetts company specialising in the application of microelectromechanical systems (MEMS) and nanotechnology to drug delivery.
BNGO vs EYPT — Head-to-Head
Income Statement — Q4 2025 vs Q4 2025
| Metric | | |
|---|---|---|
| Revenue | $8.0M | $619.0K |
| Net Profit | $-7.9M | $-67.6M |
| Gross Margin | 42.8% | — |
| Operating Margin | -107.4% | -11364.3% |
| Net Margin | -99.8% | -10922.3% |
| Revenue YoY | -2.6% | -94.7% |
| Net Profit YoY | 60.6% | -63.3% |
| EPS (diluted) | $-0.12 | $-0.82 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $8.0M | $619.0K | ||
| Q3 25 | $7.4M | $966.0K | ||
| Q2 25 | $6.7M | $5.3M | ||
| Q1 25 | $6.5M | $24.5M | ||
| Q4 24 | $8.2M | $11.6M | ||
| Q3 24 | $6.1M | $10.5M | ||
| Q2 24 | $7.8M | $9.5M | ||
| Q1 24 | $8.8M | $11.7M |
| Q4 25 | $-7.9M | $-67.6M | ||
| Q3 25 | $-8.5M | $-59.7M | ||
| Q2 25 | $-6.9M | $-59.4M | ||
| Q1 25 | $-3.1M | $-45.2M | ||
| Q4 24 | $-20.1M | $-41.4M | ||
| Q3 24 | $-44.2M | $-29.4M | ||
| Q2 24 | $-16.2M | $-30.8M | ||
| Q1 24 | $-31.4M | $-29.3M |
| Q4 25 | 42.8% | — | ||
| Q3 25 | 45.7% | — | ||
| Q2 25 | 51.6% | — | ||
| Q1 25 | 45.5% | — | ||
| Q4 24 | 41.9% | — | ||
| Q3 24 | -139.1% | 93.0% | ||
| Q2 24 | 33.3% | 85.2% | ||
| Q1 24 | 32.2% | 93.5% |
| Q4 25 | -107.4% | -11364.3% | ||
| Q3 25 | -115.9% | -6420.8% | ||
| Q2 25 | -115.8% | -1166.8% | ||
| Q1 25 | -131.1% | -199.7% | ||
| Q4 24 | -146.3% | -390.4% | ||
| Q3 24 | -722.9% | -311.2% | ||
| Q2 24 | -219.0% | -364.5% | ||
| Q1 24 | -354.9% | -285.2% |
| Q4 25 | -99.8% | -10922.3% | ||
| Q3 25 | -115.4% | -6183.4% | ||
| Q2 25 | -101.8% | -1114.3% | ||
| Q1 25 | -48.0% | -184.8% | ||
| Q4 24 | -246.5% | -357.3% | ||
| Q3 24 | -728.6% | -279.0% | ||
| Q2 24 | -208.8% | -325.3% | ||
| Q1 24 | -358.3% | -250.6% |
| Q4 25 | $-0.12 | $-0.82 | ||
| Q3 25 | $-1.59 | $-0.85 | ||
| Q2 25 | $-1.99 | $-0.85 | ||
| Q1 25 | $-1.15 | $-0.65 | ||
| Q4 24 | $-7.05 | $-0.65 | ||
| Q3 24 | $-30.92 | $-0.54 | ||
| Q2 24 | $-14.41 | $-0.58 | ||
| Q1 24 | $-35.75 | $-0.55 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $3.0M | $306.1M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $44.4M | $306.1M |
| Total Assets | $73.6M | $364.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $3.0M | $306.1M | ||
| Q3 25 | $3.1M | $204.0M | ||
| Q2 25 | $3.6M | $255.7M | ||
| Q1 25 | $3.6M | $318.2M | ||
| Q4 24 | $9.2M | $370.9M | ||
| Q3 24 | $8.8M | $253.8M | ||
| Q2 24 | $10.4M | $280.2M | ||
| Q1 24 | $15.8M | $299.3M |
| Q4 25 | $44.4M | $306.1M | ||
| Q3 25 | $49.8M | $200.2M | ||
| Q2 25 | $45.4M | $246.0M | ||
| Q1 25 | $48.2M | $298.4M | ||
| Q4 24 | $35.4M | $336.5M | ||
| Q3 24 | $48.9M | $218.7M | ||
| Q2 24 | $80.3M | $228.3M | ||
| Q1 24 | $82.8M | $249.9M |
| Q4 25 | $73.6M | $364.0M | ||
| Q3 25 | $79.1M | $251.7M | ||
| Q2 25 | $76.0M | $301.1M | ||
| Q1 25 | $78.4M | $362.6M | ||
| Q4 24 | $76.7M | $418.5M | ||
| Q3 24 | $87.4M | $300.9M | ||
| Q2 24 | $129.4M | $324.2M | ||
| Q1 24 | $158.0M | $329.2M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-4.2M | $-65.0M |
| Free Cash FlowOCF − Capex | — | $-66.0M |
| FCF MarginFCF / Revenue | — | -10667.7% |
| Capex IntensityCapex / Revenue | — | 159.3% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-243.4M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-4.2M | $-65.0M | ||
| Q3 25 | $-5.9M | $-59.4M | ||
| Q2 25 | $-3.5M | $-62.6M | ||
| Q1 25 | $-2.8M | $-53.1M | ||
| Q4 24 | $-6.5M | $-35.8M | ||
| Q3 24 | $-13.3M | $-39.0M | ||
| Q2 24 | $-21.0M | $-20.2M | ||
| Q1 24 | $-28.1M | $-31.2M |
| Q4 25 | — | $-66.0M | ||
| Q3 25 | — | $-60.2M | ||
| Q2 25 | — | $-63.8M | ||
| Q1 25 | — | $-53.4M | ||
| Q4 24 | — | $-36.2M | ||
| Q3 24 | — | $-40.6M | ||
| Q2 24 | — | $-21.1M | ||
| Q1 24 | — | $-32.4M |
| Q4 25 | — | -10667.7% | ||
| Q3 25 | — | -6226.9% | ||
| Q2 25 | — | -1196.5% | ||
| Q1 25 | — | -218.4% | ||
| Q4 24 | — | -312.7% | ||
| Q3 24 | — | -385.8% | ||
| Q2 24 | — | -222.4% | ||
| Q1 24 | — | -277.0% |
| Q4 25 | — | 159.3% | ||
| Q3 25 | — | 82.6% | ||
| Q2 25 | — | 22.9% | ||
| Q1 25 | — | 1.1% | ||
| Q4 24 | — | 3.3% | ||
| Q3 24 | — | 15.0% | ||
| Q2 24 | — | 9.5% | ||
| Q1 24 | — | 10.2% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
